SCHEMBL830535

SCHEMBL830535

CC(C)[C@@H](C(=O)Nc1ccccc1)N(C)[C@@H]1CN1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MTOR P42345 1/20 0.41
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
ATM Q13315 2/20 0.41
HTT P42858 2/20 0.41
GAA P10253 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
EPHX2 P34913 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTR1E P28566 1/20 0.40
S1PR3 Q99500 1/20 0.40
MME P08473 1/20 0.40
ACE P12821 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830498 0.81 MAPT (0.44) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL830003 0.77 MTOR (0.42) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL27141238 0.76 ALDH1A1 (0.51) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL27141240 0.76 ALDH1A1 (0.51) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL830536 0.69 MEN1 (0.44) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL830537 0.69 MEN1 (0.44) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL13149431 0.69 ALDH1A1 (0.58) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL30807716 0.69 MTOR (0.47) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL12251076 0.68 ALDH1A1 (0.61) MEN1KMT2AMAPTALDH1A1RXFP1
SCHEMBL14853301 0.68 ALDH1A1 (0.61) MEN1KMT2AMAPTALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143375-B2 Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2012-03-27 US disclosed
US-20100317832-A1 AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION ZEALAND PHARMA A/S (DK) 2010-12-16 US disclosed
WO-2008046232-A1 AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION YUDIN ANDREI K (CA) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317832-A1 AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION QDPR, VIP, AAAS MEN1 1182/4885KMT2A 2189/4885MAPT 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.